- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05450432
Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression
January 20, 2023 updated by: Cristina Cusin, MD, Massachusetts General Hospital
The study will consist of a 24-week-long trial examining outcomes in patients with Major Depressive Disorder and suicidal ideation who will receive intravenous (IV) ketamine and intranasal (IN) esketamine, compared to a large sample of matched historical controls.
Patients will be recruited from an inpatient psychiatric unit.
Eligible patients who provided informed consent will be enrolled in the study that will include a eight IV ketamine treatments, 13 esketamine treatment visits, seven long assessment visits, five short assessment visits, and daily surveys.
The study will examine the feasibility, tolerability, and efficacy of repeated IV ketamine followed by esketamine, as well as predictors of treatment response.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Cristina Cusin, MD
- Phone Number: 617-724-5510
- Email: mghketamineclinic@mgh.harvard.edu
Study Contact Backup
- Name: Julianne Origlio
- Phone Number: 617-643-2497
- Email: joriglio@mgh.harvard.edu
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Massachusetts General Hospital
-
Principal Investigator:
- Cristina Cusin, MD
-
Contact:
- Julianne Origlio
- Phone Number: 617-643-2497
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Inpatient at a psychiatric unit at MGH
- Male and female, 18-70 years of age
- Diagnosis of Major Depressive Disorder, single or recurrent, based on DSM-5 criteria, and currently experiencing a major depressive episode (MDE) at least eight weeks in duration, prior to screening
- Current suicidal ideation
- In good general health, as ascertained by medical history, physical examination, clinical laboratory evaluations, and/or ECG
- A status of non-childbearing potential or use of an acceptable form of birth control
- Access to a mobile phone or computer with internet connection
- Ability to read, understand, and provide written and dated informed consent prior to screening
- Has a treating psychiatrist, either prior to admission or at discharge from the inpatient unit
Exclusion Criteria:
- Any history of previous treatment with IV ketamine
- Pregnant or breastfeeding
- A status of childbearing potential and is not willing to use birth control during the study
- Unstable medical illness
- Current diagnosis of a moderate to severe substance use disorder, within the last six months prior to screening based on DSM-5 criteria
- History of bipolar disorder, or any psychotic symptoms in the current or previous depressive episodes
- An Axis I or Axis II Disorder, which at screening is clinically predominant to their MDD or has been predominant to their MDD at any time within six months prior to screening (i.e., eating disorder, OCD, PTSD)
- Currently receiving ECT treatment
- Currently receiving frequent or high dose benzodiazepines, opiates, barbiturates, or other CNS depressant medications
- Has dementia, delirium, amnestic, or any other primary cognitive disorder
- Has a clinically significant abnormality on the screening physical examination that might affect safety, study participation, or confound interpretation of study results
- Inability to consent to or comply with the study procedures.
- Other medical issues that might affect safety, study participation, or confound interpretation of study results
- Inability to comply with study safety procedures, including having reliable escorts to and from visits
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Ketamine and Esketamine Treatment
All study subjects will receive intravenous (IV) ketamine and intranasal (IN) esketamine treatment.
|
Study participants will start treatment including two ketamine infusion visits per week during the acute phase, for up to eight ketamine infusion visits.
Participants will then be transitioned to maintenance with intranasal esketamine.
After one month from the eighth ketamine infusion visit, participants will initiate weekly esketamine for 12 weeks, for a total of 13 esketamine treatments.
The esketamine visits will happen as per standard of care at the clinic and as instructed by the SPRAVATO Risk Evaluation and Mitigation Strategy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility - Retention
Time Frame: 24 weeks
|
For examining the feasibility of treatment with ketamine and esketamine, descriptive analyses will be conducted to assess participants' retention across study visits.
|
24 weeks
|
Feasibility - Drop-out Rates
Time Frame: 24 weeks
|
For examining the feasibility of treatment with ketamine and esketamine, descriptive analyses will be conducted to assess participants' drop-out rates across participation in the study.
|
24 weeks
|
Tolerability - Cognitive Function and Side Effects
Time Frame: Weeks 0, 1, 2, 3, 4, 8, and 12-24
|
In regard to tolerability, the investigators will closely monitor cognitive functions and side effects during the administration of ketamine and esketamine.
|
Weeks 0, 1, 2, 3, 4, 8, and 12-24
|
Tolerability - Dosage of Treatment
Time Frame: Change between weeks 0, 4, 6, 8, 10, 12, 14, 16, 20, 22, and 24
|
In regard to tolerability, the investigators will record the Necessary Clinical Adjustments (NCAs) for dosage of ketamine and esketamine treatments.
|
Change between weeks 0, 4, 6, 8, 10, 12, 14, 16, 20, 22, and 24
|
Tolerability - Frequency of Treatment
Time Frame: Change between weeks 0, 4, 6, 8, 10, 12, 14, 16, 20, 22, and 24
|
In regard to tolerability, the investigators will record the Necessary Clinical Adjustments (NCAs) for the frequency of ketamine and esketamine administration.
|
Change between weeks 0, 4, 6, 8, 10, 12, 14, 16, 20, 22, and 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy - Treatment Response
Time Frame: Weeks 4, 8, and 12-24
|
Descriptive analyses will be performed for percentage of responders (defined as 35% improvement on the QIDS-16) at the end of the IV ketamine acute phase, after the eighth ketamine infusion, and across the esketamine maintenance phase.
|
Weeks 4, 8, and 12-24
|
Efficacy - Trajectory of Suicidal Ideation
Time Frame: 24 weeks
|
The change in participants' suicidal ideation will be examined over time and compared to historical controls.
|
24 weeks
|
Efficacy - Trajectory of Depression
Time Frame: 24 weeks
|
The change in participants' depression will be examined over time and compared to historical controls.
|
24 weeks
|
Efficacy - Hospital Readmission Rates
Time Frame: 24 weeks
|
The change in participants' hospital readmission rates will be examined over time and compared to historical controls.
|
24 weeks
|
Efficacy - Prevalence of Suicidal Behavior
Time Frame: 24 weeks
|
The occurrence of suicidal behavior (gestures, attempts, and completed suicide) among participants will be examined over time and compared to historical controls.
|
24 weeks
|
Efficacy - Healthcare Utilization
Time Frame: 24 weeks
|
The change in participants' healthcare utilization rates will be examined over time and compared to historical controls.
|
24 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Exploratory Aim - Predictors of Treatment Response
Time Frame: 24 weeks
|
Exploratory aims will be examined, including predictors of treatment response (defined as 35% improvement in QIDS score) at the end of the acute and maintenance phases.
|
24 weeks
|
Exploratory Aim - Predictors of Suicidal Ideation Relapse
Time Frame: 24 weeks
|
Exploratory aims will be examined, including predictors of suicidal ideation relapse (defined as SSI5>1) during time intervals between intravenous ketamine visits and during the esketamine maintenance phase.
|
24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 13, 2022
Primary Completion (Anticipated)
June 1, 2025
Study Completion (Anticipated)
June 1, 2025
Study Registration Dates
First Submitted
June 16, 2022
First Submitted That Met QC Criteria
July 5, 2022
First Posted (Actual)
July 8, 2022
Study Record Updates
Last Update Posted (Actual)
January 25, 2023
Last Update Submitted That Met QC Criteria
January 20, 2023
Last Verified
January 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Mood Disorders
- Self-Injurious Behavior
- Depression
- Depressive Disorder
- Suicide
- Depressive Disorder, Major
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Dissociative
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Psychotropic Drugs
- Antidepressive Agents
- Ketamine
- Esketamine
Other Study ID Numbers
- 2022P000972
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
IPD Plan Description
The investigators do not plan to share IPD.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depressive Disorder
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...Fondo de Investigacion SanitariaUnknown
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
AccexibleRecruitingMajor Depressive Disorder (MDD)Spain
Clinical Trials on Ketamine
-
Grace Lim, MD, MSNational Institute of Mental Health (NIMH)RecruitingPain, Postoperative | Depression, PostpartumUnited States
-
Ullevaal University HospitalUniversity of OsloCompleted
-
Assistance Publique - Hôpitaux de ParisCompletedArthroplasty, Replacement, HipFrance
-
Assiut UniversityCompletedKetamine Causing Adverse Effects in Therapeutic UseEgypt
-
The University of Texas Health Science Center,...TerminatedPost Partum DepressionUnited States
-
Lotus Clinical Research, LLCiX Biopharma Ltd.Completed
-
Lawson Health Research InstituteUnknownBone Fractures | Dislocations
-
Antonios LikourezosCompleted
-
Children's Hospital of MichiganCompletedModerate, Deep Sedation